Company Overview

Cardiol Therapeutics Inc. is a Canadian clinical-stage biotechnology company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of cardiovascular disease. The company operates within the biotechnology and pharmaceutical industries, with a primary emphasis on inflammatory heart conditions that currently have limited approved treatment options. Its lead programs are centered on pharmaceutically manufactured cannabidiol formulations designed to target inflammation associated with cardiac disease.

The company’s principal revenue and value drivers are tied to clinical development activities, intellectual property, and advancement of its therapeutic pipeline rather than commercial product sales. Its primary programs include CardiolRx™, an oral cannabidiol formulation being evaluated for inflammatory and fibrotic heart disease indications, and CRD-38, a proprietary subcutaneous formulation intended for heart failure-related applications. Cardiol Therapeutics primarily serves the cardiovascular therapeutics market, including physicians, clinical research institutions, and future specialty pharmaceutical channels. The company was founded in Canada and evolved from early-stage cannabinoid pharmaceutical development into a cardiovascular-focused clinical biotechnology company listed on the Toronto Stock Exchange under the symbol CRDL and on Nasdaq under the symbol CRDL.

Business Operations

Cardiol Therapeutics operates as a single biotechnology-focused business centered on research, clinical development, regulatory advancement, and intellectual property management. The company’s activities include conducting clinical trials, manufacturing pharmaceutical-grade formulations, managing regulatory submissions, and advancing pre-commercial cardiovascular therapies. Its operations are primarily concentrated in North America, though clinical development activities involve collaborations with international research institutions and trial sites.

The company’s core assets include proprietary cannabidiol-based formulations, clinical-stage cardiovascular drug candidates, and related intellectual property portfolios. CardiolRx™ has been investigated in clinical programs involving recurrent pericarditis and other inflammatory cardiac conditions. The company works with contract research organizations, pharmaceutical manufacturing partners, and academic medical centers to support development activities. Public disclosures identify collaborations with clinical investigators and healthcare institutions rather than large-scale commercial joint ventures. Data regarding material equity joint ventures or majority-owned operating subsidiaries is inconclusive based on available public sources.

Strategic Position & Investments

Cardiol Therapeutics’ strategy is focused on becoming a specialized cardiovascular therapeutics company targeting inflammation-driven heart disease. The company has prioritized advancing late-stage clinical development programs, strengthening intellectual property protections, and generating clinical evidence to support regulatory pathways in underserved cardiovascular indications. Management has emphasized differentiated positioning through pharmaceutical-grade cannabidiol formulations manufactured under regulated standards, distinguishing its products from non-pharmaceutical cannabinoid products.

Key investments have included clinical trial expansion, manufacturing capabilities for pharmaceutical-grade formulations, and continued development of CRD-38 and CardiolRx™. The company has also invested in regulatory and scientific partnerships supporting clinical development in the United States and Canada. Cardiol Therapeutics operates within the emerging intersection of cannabinoid science and cardiovascular medicine, particularly in areas involving inflammation, fibrosis, and immune-mediated cardiac disease. No major transformative acquisitions comparable to large pharmaceutical M&A transactions were identified in public filings and major financial reporting.

Geographic Footprint

Cardiol Therapeutics is headquartered in Oakville, Ontario, Canada, and maintains operational and clinical activities primarily across Canada and the United States. The company’s securities are publicly traded in both Canadian and U.S. capital markets, supporting access to North American biotechnology investors and institutional funding sources.

Its clinical and regulatory presence is concentrated in North America, though clinical trial activities may involve international investigators and multicenter research participation. The company’s commercial ambitions are aligned with major cardiovascular pharmaceutical markets, particularly the United States, which represents the largest target market for specialty cardiovascular therapeutics. Publicly available information does not indicate a significant standalone commercial infrastructure outside North America at this stage of development.

Leadership & Governance

Cardiol Therapeutics is led by an executive team with backgrounds in biotechnology, pharmaceuticals, finance, and cardiovascular medicine. Leadership has consistently emphasized disciplined clinical development, regulatory execution, and scientific validation of the company’s cardiovascular-focused cannabinoid therapies. Governance oversight is provided through a board of directors with experience in healthcare, biotechnology commercialization, and public company management.

Key executives include:

• David Elsley – President and Chief Executive Officer
• Andrew Hamer – Chief Financial Officer
• Guido Baechler – Chief Medical Officer
• Michael W. Wecker – Vice President, Research and Development

The company’s leadership strategy has focused on advancing clinically differentiated therapies for inflammatory heart disease while maintaining a capital-efficient development model typical of clinical-stage biotechnology companies. Public filings, including SEC filings and Canadian securities disclosures, indicate continued emphasis on regulatory progress, clinical data generation, and long-term cardiovascular market positioning.